LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 445

Search options

  1. Article ; Online: Clinical challenges in applying the new lung function test interpretive strategies: navigating pitfalls and possible solutions.

    Ora, Josuel / Rogliani, Paola

    The European respiratory journal

    2024  Volume 63, Issue 1

    Language English
    Publishing date 2024-01-25
    Publishing country England
    Document type Letter
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.01439-2023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease.

    Calzetta, Luigino / Rogliani, Paola

    Expert review of respiratory medicine

    2024  Volume 17, Issue 12, Page(s) 1273–1283

    Abstract: Objectives: Single-inhaler triple therapies (SITTs) have never been directly compared in randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD). Cochrane recommends the Bayesian approach for indirect comparisons but a ... ...

    Abstract Objectives: Single-inhaler triple therapies (SITTs) have never been directly compared in randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD). Cochrane recommends the Bayesian approach for indirect comparisons but a frequentist network meta-analysis (NMA) reported superiority of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) over other SITT. We assessed the most appropriate inference method for NMA characterized by between-study heterogeneity on SITT in COPD.
    Methods: Bayesian and frequentist NMA were performed on RCTs investigating the effect of SITT on exacerbations and trough forced expiratory volume in the 1
    Results: The included RCTs (ETHOS, FULFIL, IMPACT, KRONOS 200812) reported significant between-study heterogeneity (I
    Conclusion: Indirect comparison should be performed via Bayesian approach instead of frequentist inference with a fixed-effect model. Claiming the superiority of a specific medication over other therapies should be confirmed by findings originating from well-designed RCTs.
    MeSH term(s) Humans ; Bronchodilator Agents/adverse effects ; Network Meta-Analysis ; Administration, Inhalation ; Fluticasone/therapeutic use ; Androstadienes/therapeutic use ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Nebulizers and Vaporizers ; Benzyl Alcohols/adverse effects ; Chlorobenzenes/adverse effects ; Quinuclidines/adverse effects ; Drug Combinations
    Chemical Substances fluticasone furoate (JS86977WNV) ; GSK573719 ; vilanterol (028LZY775B) ; Bronchodilator Agents ; Fluticasone (CUT2W21N7U) ; Androstadienes ; Benzyl Alcohols ; Chlorobenzenes ; Quinuclidines ; Drug Combinations
    Language English
    Publishing date 2024-02-16
    Publishing country England
    Document type Meta-Analysis ; Journal Article ; Review
    ZDB-ID 2479146-5
    ISSN 1747-6356 ; 1747-6348
    ISSN (online) 1747-6356
    ISSN 1747-6348
    DOI 10.1080/17476348.2024.2316167
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6963: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab".

    Calzetta, Luigino / Rogliani, Paola

    Advances in therapy

    2022  Volume 39, Issue 8, Page(s) 3857–3861

    MeSH term(s) Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Disease Progression ; Humans
    Chemical Substances Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; benralizumab (71492GE1FX)
    Language English
    Publishing date 2022-06-22
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-022-02213-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2101: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Pharmacological Interpretation of the Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease: Insights from ENHANCE Trials.

    Calzetta, Luigino / Cazzola, Mario / Rogliani, Paola

    American journal of respiratory and critical care medicine

    2023  Volume 209, Issue 2, Page(s) 224–225

    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Isoquinolines/pharmacology ; Pyrimidinones
    Chemical Substances ensifentrine (3E3D8T1GIX) ; Isoquinolines ; Pyrimidinones
    Language English
    Publishing date 2023-11-06
    Publishing country United States
    Document type Letter
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202308-1355LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies.

    Rogliani, Paola / Calzetta, Luigino

    Journal of experimental pharmacology

    2022  Volume 14, Page(s) 1–5

    Abstract: The IRIDIUM and ARGON studies provided positive findings concerning the benefits of the once-daily triple mometasone furoate/indacaterol/glycopyrronium (MF/IND/GLY) fixed-dose combination (FDC) for the treatment of uncontrolled asthma, at the least by a ... ...

    Abstract The IRIDIUM and ARGON studies provided positive findings concerning the benefits of the once-daily triple mometasone furoate/indacaterol/glycopyrronium (MF/IND/GLY) fixed-dose combination (FDC) for the treatment of uncontrolled asthma, at the least by a strict statistical point of view. In the IRIDIUM study patients received medium-dose (MD) or high-dose (HD) MF/IND/GLY or MF/IND oncex daily or HD fluticasone/salmeterol (FLU/SAL) twice daily; in the ARGON study patients received MD or HD MF/IND/GLY once daily or HD FLU/SAL twice daily + tiotropium (TIO) once daily. Since a detailed interpretation of clinical results has not yet been performed, we provided the clinical interpretation of efficacy outcomes resulting from the IRIDIUM and ARGON studies according to the currently available minimal clinically important difference (MCID) thresholds. The triple MF/IND/GLY FDC elicited beneficial clinically relevant effects compared to active comparators in asthmatic patients, according to the levels of ICS doses, by generally achieving and overcoming the MCID. The level of clinical benefit was usually greater in patients treated with HD-MF/IND/GLY compared to those treated with MD-MF/IND/GLY. Overall, HD-MF/IND/GLY induced greater clinically relevant benefits even when compared to HD-FLU/SAL + TIO. Considering that a balanced triple MF/IND/GLY FDC with MD ICS resulted as effective as HD-MF/IND in preventing moderate or severe exacerbations, thus triple ICS/LABA/LAMA FDCs with MD ICS should be considered for the treatment not only of uncontrolled asthma but also for those patients suffering from less severe forms of disease with airflow limitation as well as a possible as-needed therapeutic option.
    Language English
    Publishing date 2022-01-11
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2587465-2
    ISSN 1179-1454
    ISSN 1179-1454
    DOI 10.2147/JEP.S336304
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?

    Cazzola, Mario / Rogliani, Paola / Matera, Maria Gabriella

    Drugs

    2023  Volume 83, Issue 11, Page(s) 957–965

    Abstract: A growing number of clinical trials are documenting that adding a long-acting muscarinic antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and a long-acting ... ...

    Abstract A growing number of clinical trials are documenting that adding a long-acting muscarinic antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and a long-acting β
    MeSH term(s) Humans ; Muscarinic Antagonists/pharmacology ; Muscarinic Antagonists/therapeutic use ; Adrenergic beta-2 Receptor Agonists/pharmacology ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Administration, Inhalation ; Asthma/drug therapy ; Lung ; Drug Therapy, Combination ; Adrenal Cortex Hormones ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Bronchodilator Agents/therapeutic use
    Chemical Substances Muscarinic Antagonists ; Adrenergic beta-2 Receptor Agonists ; Adrenal Cortex Hormones ; Bronchodilator Agents
    Language English
    Publishing date 2023-06-12
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 120316-2
    ISSN 1179-1950 ; 0012-6667
    ISSN (online) 1179-1950
    ISSN 0012-6667
    DOI 10.1007/s40265-023-01897-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 762: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?

    Cazzola, Mario / Rogliani, Paola / Blasi, Francesco

    International journal of chronic obstructive pulmonary disease

    2023  Volume 18, Page(s) 1959–1964

    Abstract: The complexity of COPD implies the need to identify groups of patients with similar clinical characteristics and prognosis or treatment requirements. This is why much attention has been paid to identifying the different clinical phenotypes by ... ...

    Abstract The complexity of COPD implies the need to identify groups of patients with similar clinical characteristics and prognosis or treatment requirements. This is why much attention has been paid to identifying the different clinical phenotypes by investigating the clinical expression of the disease, and endotypes by studying the biological networks that enable and limit reactions. However, this approach is complicated because one endotype gives rise to one or more clinical characteristics, and clinical phenotypes can be derived from several endotypes. To simplify the approach, a new taxonomic classification of COPD based on the different causes (or etiotypes) has been proposed, but these etiotypes have not yet been validated. A simpler method is the so-called tractable traits approach, which is free from any designation of the disorder to be treated and does not present the criticality of using etiotypes. A large randomised controlled trial on using the treatable traits approach in COPD is still lacking. Nevertheless, this approach is already applied by following the GOLD strategy. However, its application is complicated because several potentially treatable traits have been identified within the pulmonary domain, the extrapulmonary domain, and the behavioural/risk factor domain. In addition, the hierarchy of the dominant treatable traits has not yet been established, and they change over time both spontaneously and because of treatment. This means that the patients being treated according to the tractable traits approach must be constantly followed over time so that the therapy is focused on their temporal needs.
    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/genetics ; Pulmonary Disease, Chronic Obstructive/therapy ; Phenotype ; Risk Factors
    Language English
    Publishing date 2023-09-08
    Publishing country New Zealand
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 2212419-6
    ISSN 1178-2005 ; 1176-9106
    ISSN (online) 1178-2005
    ISSN 1176-9106
    DOI 10.2147/COPD.S428391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Mortality in ETHOS: A Question of "Power".

    Rogliani, Paola / Calzetta, Luigino

    American journal of respiratory and critical care medicine

    2021  Volume 203, Issue 7, Page(s) 926–927

    MeSH term(s) Budesonide ; Double-Blind Method ; Formoterol Fumarate ; Glycopyrrolate ; Humans ; Pulmonary Disease, Chronic Obstructive
    Chemical Substances Budesonide (51333-22-3) ; Glycopyrrolate (V92SO9WP2I) ; Formoterol Fumarate (W34SHF8J2K)
    Language English
    Publishing date 2021-02-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202012-4328LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Response to letter to the editor. Again on IMPACT: exacerbation after abrupt discontinuation of ICS and pneumonia in fluticasone furoate-containing FDCs.

    Rogliani, Paola / Calzetta, Luigino

    Expert opinion on pharmacotherapy

    2021  Volume 22, Issue 7, Page(s) 943–945

    MeSH term(s) Androstadienes/adverse effects ; Humans ; Pneumonia/chemically induced ; Pneumonia/drug therapy ; Pulmonary Disease, Chronic Obstructive/drug therapy
    Chemical Substances Androstadienes ; fluticasone furoate (JS86977WNV)
    Language English
    Publishing date 2021-03-30
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2021.1898746
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update.

    Matera, Maria Gabriella / Rinaldi, Barbara / Calzetta, Luigino / Rogliani, Paola / Cazzola, Mario

    Expert opinion on pharmacotherapy

    2024  Volume 24, Issue 18, Page(s) 2133–2142

    Abstract: Introduction: Strong scientific evidence and large experience support the use of β: Areas covered: Recent research on novel β: Expert opinion: Compounds that preferentially activate a ... ...

    Abstract Introduction: Strong scientific evidence and large experience support the use of β
    Areas covered: Recent research on novel β
    Expert opinion: Compounds that preferentially activate a G
    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Receptors, Adrenergic, beta-2/metabolism ; Receptors, Adrenergic, beta-2/therapeutic use ; Signal Transduction ; Adrenergic beta-2 Receptor Agonists/pharmacology ; Adrenergic beta-2 Receptor Agonists/therapeutic use
    Chemical Substances Receptors, Adrenergic, beta-2 ; Adrenergic beta-2 Receptor Agonists
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2282673
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top